Mounjaro tirzepatide injection

Mounjaro (tirzepatide) is a once-weekly injectable medication developed by Eli Lilly and Company. It is primarily used to manage type 2 diabetes in adults, helping to improve blood sugar control alongside diet and exercise. Tirzepatide works as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, which means it mimics the action of these hormones to stimulate insulin release, reduce glucagon levels, slow gastric emptying, and promote satiety. This mechanism not only helps regulate blood glucose but can also lead to weight loss, making it a popular choice for patients with type 2 diabetes who are also managing obesity.